AstraZeneca and Merck attain FDA nod for a pancreatic cancer drug
Category: #health  By Saipriya Iyer  Date: 2019-12-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

AstraZeneca and Merck attain FDA nod for a pancreatic cancer drug

The drug, dubbed Lynparza, is currently approved in almost 65 countries for the maintenance treatment of platinum-sensitive lapsed ovarian cancer.

British pharmaceutical firm AstraZeneca and Merck & Co. Inc. recently announced that its drug candidate olaparib, which is also known as Lynparza, has received approval from the U.S. Food and Drug Administration.

Reportedly, the drug is formulated to treat patients with pancreatic cancer that have mutations of genes which aids in suppressing tumors. Moreover, it is slated to double the life expectancy of pancreatic cancer patients.

As per reports, olaparib was cleared by the FDA to treat adults that have metastatic pancreatic cancer and whose health hasn’t deteriorated after 16 weeks of chemotherapy. The trial’s finding, which were published in The New England Journal of Medicine, suggested that the medicine minimized the risk of death or progression by 47%.

According to Dave Fredrickson, Executive VP of Oncology Business Unit, AstraZeneca, people previously suffering from advanced pancreatic cancer received poor outcomes because of the limited treatment advances over the past decade and aggressive nature of the disease. Lynparza comes as the only targeted drug in biomarker-selected patients going through advanced pancreatic cancer which is approved by the FDA.

Meanwhile, Roy Baynes, Chief Medical Officer & Senior Vice President, Merck Research Labs, revealed that the expanded approval of Lynparza comes as a substantial landmark for patients and reinforces the findings of germline BRCA testing in subjects with this disease.

Prior to the FDA approval, Merck & Co. Inc. and AstraZeneca had made headlines when Lynparza bagged approval from the Chinese regulators for treating a form of ovarian cancer. Sources close to the news claimed that the approval was based on Lynparza’s results from a late-stage trial in which it reduced the risk of death or disease progression by 70% when equated to placebo.
 

Source Credit: https://www.foxbusiness.com/lifestyle/astra-merck-get-fda-ok-for-pancreatic-cancer-drug



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Copper3D unveils antimicrobial device to curb HIV risk via breastmilk
Copper3D unveils antimicrobial device to curb HIV risk via breastmilk
By Saipriya Iyer

Copper3D, a Chile- and U.S.-based antibacterial solutions provider, has recently worked on a project to create an antibacterial 3D printed device to mitigate the risk of HIV transmission during breastfeeding. The compa...

Tetra commences PoC clinical trial of PPP003v for companion dogs
Tetra commences PoC clinical trial of PPP003v for companion dogs
By Saipriya Iyer

Tetra Bio-Pharma Inc., a Canadian pharmaceutical firm that specializes in cannabinoid-derived drug therapy, has recently initiated a clinical study of synthetic cannabinoid therapy (PPP003v) for ophthalmic eye pain in ...

Satipharm begins clinical trial of CBD capsules for treating menopause
Satipharm begins clinical trial of CBD capsules for treating menopause
By Saipriya Iyer

Cannabis was prior considered to possess various medicinal benefits for treating diseases. However, after years of restriction, the scientific community is finally exploring the medical avenues of CBD by conducting adv...